An observational study in Resectable Pancreatic Cancer, sponsored by Ruijin Hospital. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Ruijin Hospital · Observational
This trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).
This trial is a retrospective, observational study based on real-world data obtained from the Health Information System (HIS) of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's enrollment of 64 is below the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Ruijin Hospital is the lead sponsor of 635 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer
Exclusion Criteria:
Nimotuzumab plus adjuvant chemotherapy
Drug: Nimotuzumab
adjuvant chemotherapy alone (without Nimotuzumab)
Nimotuzumab (400mg) was given weekly
Also known as: Taixinsheng
overall survival (OS）
The primary endpoint is overall survival (OS), defined as the time from the start of surgery to the date of death due to any cause.
Time frame: approximately 84 months
disease-free survival (DFS)
DFS is defined as the time from surgical resection to the first tumor recurrence/progression or death due to any cause.
Time frame: approximately 84 months
locoregional recurrence-free survival (LRRFS)
LRRFS is defined as the time from surgical treatment to clinically or radiographically confirmed local recurrence and/or regional progression at follow-up.
Time frame: approximately 84 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruijin Hospital